Rozanolixizumab, also known as UCB7665, Rystiggo 140 mg/ml solution for injection, -
MOG001
Phase 3 small_molecule active
Quick answer
Rozanolixizumab, also known as UCB7665, Rystiggo 140 mg/ml solution for injection, - for Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD) is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active